Trevi Therapeutics (TRVI) vs Vera Therapeutics (VERA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Trevi Therapeutics (TRVI) has outperformed Vera Therapeutics (VERA) over the past year, gaining 21.5% versus a loss of 10.6%. Over five years, TRVI leads with a +1235.0% price change compared with -15.2% for VERA. Trevi Therapeutics is the larger company by market cap ($1.90 billion vs $1.84 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | TRVI | VERA |
|---|---|---|
| Share price | $13.35 | $25.45 |
| Market cap | $1.90B | $1.84B |
| 1-day change | -2.70% | -4.86% |
| YTD return | +6.63% | -49.74% |
| 1-year return | +21.47% | -10.58% |
| 5-year return | +1235.00% | -15.17% |
| EPS (TTM) | $-0.40 | $-5.90 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-42.76M | $-299.62M |
| 52-week high | $20.22 | $56.05 |
| 52-week low | $9.82 | $25.08 |
| Distance from 52-week high | -33.98% | -54.59% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +111.09% | +180.39% |
| Average volume | 2.00M | 1.95M |
| Shares outstanding | 142.56M | 72.30M |
| Employees | 34 | 362 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TRVI has outperformed VERA by 32.1 percentage points over the past year.
About Trevi Therapeutics
TRVI stock →Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough.
Health Care · Biotechnology: Pharmaceutical Preparations · 34 employees
About Vera Therapeutics
VERA stock →Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 362 employees
TRVI vs VERA FAQ
Which is bigger, Trevi Therapeutics or Vera Therapeutics?
Trevi Therapeutics (TRVI) is larger, with a market capitalization of $1.90B compared with $1.84B for Vera Therapeutics (VERA).
Which stock has performed better over the past year, TRVI or VERA?
TRVI returned +21.47% over the past 12 months, compared with -10.58% for VERA (price return, excluding dividends). Past performance does not predict future results.
Are Trevi Therapeutics and Vera Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.